1 Min Read
LONDON, Jan 2 (Reuters) - Silence Therapeutics PLC : * Appointment of chief medical officer * appointed Michael Khan to oversee Phase II clinical trials
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.